BioCentury
ARTICLE | Clinical News

Signifor LAR pasireotide regulatory update

February 17, 2014 8:00 AM UTC

Novartis disclosed in its 4Q13 earnings that it submitted regulatory applications in the U.S. and EU for Signifor LAR pasireotide to treat patients with acromegaly for whom medical therapy is appropri...